FLT3 and myeloid sarcoma: Bone marrow transplantation or hematopoietic stem cell transplantation (HCST) and targeted therapy based on agents such as FLT3 inhibitors, farnesyltransferase inhibitors, histone deacetylase inhibitors, and DNA methyltransferase inhibitors could also be considered as therapeutic options for MS patients.